A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma.

Trial Profile

A Phase II Study of PF-03446962 in Patients with Advanced Malignant Pleural Mesothelioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Ascrinvacumab (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2016 Results published in the Journal of Thoracic Oncology
    • 15 Feb 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 07 Feb 2014 Planned End Date changed from 1 Jun 2014 to 1 Sep 2014, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top